{{overview_title}}
{{overview_content}}
{{mechanism_title}}
{{mechanism_content}}
{{benefits_title}}
{{research_title}}
{{research_content}}
{{safety_title}}
{{safety_content}}
Recommended products
Research peptides selected for quality and purity:
Top Pick
GHK-Cu
Anti-Aging Compound
Frequently Asked Questions
Is tirzepatide the same as Mounjaro and Zepbound?
Yes. Tirzepatide is the active ingredient in both. Mounjaro is the brand approved for type 2 diabetes, while Zepbound is the brand approved for chronic weight management. The molecule is identical; only the indication and branding differ.
How much weight can you lose on tirzepatide?
In the SURMOUNT-1 trial, adults without diabetes lost an average of about 15% at 5 mg and roughly 20-22% at 15 mg over 72 weeks, compared with about 3% on placebo. Individual results vary based on dose, lifestyle, and adherence.
What makes tirzepatide different from semaglutide?
Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors, whereas semaglutide activates only the GLP-1 receptor. In trials, tirzepatide has generally produced greater average weight loss and HbA1c reduction, attributed largely to the added GIP activity.
What are the most common side effects of tirzepatide?
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. They are usually mild to moderate and tend to ease over time, which is why dosing is titrated slowly. It also carries a boxed warning for thyroid C-cell tumors seen in rodents.
Is tirzepatide safe and FDA approved?
Tirzepatide is FDA approved for type 2 diabetes (2022) and chronic weight management (2023) and is a prescription-only medication. "Safe" depends on the individual; it has important contraindications and risks. This guide is educational only — consult a healthcare professional before considering it.
Sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.
- Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.
- Garvey WT, Frias JP, Jastreboff AM, et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet.
- Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nature Medicine.
- Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA.
- Coskun T, Sloop KW, Loghin C, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism.